Triple therapy halves exacerbations in moderate-to-severe COPD

October 08, 2009

Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting β-agonist (LABA), an inhaled corticosteroid (ICS) and an anti-muscarinic agent, according to researchers in Germany.

In the study, which will appear in the October 15 issue of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine, researchers found that adding budesonide, an ICS, and formoterol, a LABA, to the anti-muscarinic agent, tiotropium, reduced the rate of severe exacerbations in COPD patients by 62 percent. Triple therapy also resulted in significant improvements on a number of outcome parameters in COPD patients, including lung function, signs and symptoms, and quality of life.

"This approach is of interest because the goal of COPD management is to achieve optimal control," wrote lead author, Prof. Tobias Welte, M.D., head of the Department of Respiratory Medicine of the Hannover Medical School in Germany.

While current guidelines suggest using both LABA and/or muscarinic antagonists and ICS in only a small number of patients, triple therapy is more widely used in clinical practice than officially recommended, but the benefits have never been demonstrated in a randomized controlled trial.

"We wanted to evaluate the effect of budesonide/formoterol combined with the tiotropium on lung function, patient-centered clinical outcomes (symptoms, health-related quality of life, exacerbations and morning activities), and tolerability in patients with COPD," said Dr. Welte.

The researchers recruited more than 600 patients with moderate to severe COPD to participate in the randomized, double-blind, multi-center, parallel group trial. Prior to the beginning of the study, enrolled patients stopped their use of LABA and ICS medications for two and four weeks respectively. Two weeks prior to the start of the trial, every patient was given a tiotropium (18 μg) inhaler to use daily and as needed as a reliever medication. Patients were then randomized to use either tiotropium plus budesonide and formoterol or tiotropium plus placebo twice daily. They were assessed at the beginning of the run-in period, then at weeks zero, one, six and 12.

After one week, patients on triple therapy increased their pre-dose FEV1 clinic values by six percent over than patients on tritropium alone. There was an even greater improvement in post-dose readings among triple-therapy patients, which were about 12 percent better than those on tiotropium alone.

Onset of symptom relief was also significantly quicker in the triple therapy group. "In some cases, we found that patients experienced an almost immediate relief, whereas those who were treated with placebo had a greater lag time between dosing and relief," said Dr. Welte.

Health status in the triple therapy group, as measured by the St. George's Respiratory Questionnaire for COPD (SGRQ-C) improved on average by 3.8 units. While four points is considered the minimum clinically relevant increment in most studies, more than half of triple therapy patients, as compared to 40 percent of placebo patients, experienced the clinically significant four-point-or-greater increase in SGRQ-C scores.

The researchers also found significant improvements in morning activities in the triple therapy group, beginning at one week and sustained throughout. "Patients could easier wash themselves, get dressed, eat breakfast and walk around early in the morning," said Dr. Welte.

But perhaps most significantly, the triple therapy treatment group had fewer than half the severe exacerbations of the placebo group. In the triple therapy group, 7.6 percent experienced severe exacerbations, compared to 18.5 percent in the placebo group. Those in the triple therapy treatment group also had fewer hospitalizations and a longer time to hospitalization than the placebo group.

"This is the first clinical study to directly evaluate the clinical efficacy of combining budesonide/formoterol with tiotropium in patients with COPD," said Dr. Welte. "This treatment approach was associated with marked improvements in various assessments at the clinic and at home in the morning compared with tiotropium alone. In addition, a significant 62-percent reduction was seen in severe exacerbations. Future research will evaluate the differences between triple and double (formoterol/tiotropium) therapy, may use longer study periods, and--in basic research experiments--will try to explain why the triple therapy is so successful."
-end-


American Thoracic Society

Related COPD Articles from Brightsurf:

Promising therapeutic approach against COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common and deadliest diseases worldwide.

COPD underdiagnosed in older adults, but can be managed
''Recognizing and Treating COPD in Older Adults'' the latest issue of the What's Hot newsletter from The Gerontological Society of America, addresses what is known about the prevalence, incidence, and impact of chronic obstructive pulmonary disease (COPD) in older adults.

Undersized airways may explain why nonsmokers get COPD
A mismatch between airway and lung size may explain why some nonsmokers get COPD and some heavy smokers do not, according to a new study from Columbia University Irving Medical Center.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

COPD as a lung stem cell disease
Two internationally renowned stem cell researchers at the University of Houston have found an abundance of abnormal stem cells in the lungs of patients who suffer from Chronic Obstructive Pulmonary Disease (COPD), a leading cause of death worldwide.

New hope for COPD patients possible with in-home device
In a new paper published Feb. 4 in JAMA, Mayo Clinic researchers describe the benefits of in-home noninvasive ventilation therapy, which includes a type referred to as bilevel positive airway pressure, or BiPAP -- for many patients with chronic obstructive pulmonary disease (COPD).

COPD appears to cause more severe symptoms in women
Women who develop COPD report smoking fewer cigarettes than men; and yet, women experience greater breathing impairments, are subjected to more acute exacerbations of symptoms and report lower quality of life than men with the disease, according to research presented at ATS 2019.

African-Americans with COPD appear less likely to use pulmonary rehab
African-American patients with chronic obstructive pulmonary disease, or COPD, are less likely to participate in pulmonary rehabilitation programs than white patients, even when there are programs nearby.

COPD and type 2 diabetes
COPD and type 2 diabetes are two highly prevalent global health conditions associated with high mortality and morbidity.

Read More: COPD News and COPD Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.